Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Doctors Discuss Strategies For Responding To Recent Medtronic ICD Recall

This article was originally published in The Gray Sheet

Executive Summary

Physicians are using Medtronic'sCareLink remote patient monitoring network to closely follow patients implanted with potentially defective ICDs for the primary prevention of sudden cardiac death

You may also be interested in...



Lack Of Device Identifiers On Recalled Cardiac Devices Cost Medicare $1.5Bn, OIG Says

Medicare lost $1.5bn in claims over a 10-year period to cover procedures to fix or replace seven faulty cardiac devices due to the lack of product-specific information on its claims form for malfunctioning defibrillators and pacemakers, says the US HHS Office of Inspector General. Recalls of Medtronic, Boston Scientific and Abbott/St. Jude Medical cardiac rhythm management devices are likely behind most of the cost.

ICD, Pacemaker Failure Rates Essential To Replacement Decision – JAMA

The failure rate for a device under advisory is the most important criterion physicians and patients should take into account when deciding whether to replace an implantable cardioverter defibrillator or pacemaker, according to an article in the July 26 Journal of the American Medical Association.

ICD, Pacemaker Failure Rates Essential To Replacement Decision – JAMA

The failure rate for a device under advisory is the most important criterion physicians and patients should take into account when deciding whether to replace an implantable cardioverter defibrillator or pacemaker, according to an article in the July 26 Journal of the American Medical Association.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel